Axsome Therapeutics, Inc discovered AXS-12 novel therapy for the treatment of cataplexy in patients with narcolepsy. AXS-12 is an oral, highly selective and potent norepinephrine reuptake inhibitor.
AXS-12, developed for cataplexy highlights its potential and provides meaningful benefit and substantial improvement for patients over currently available treatment options living with this debilitating condition. In addition, AXS-12 promotes wakefulness, maintain muscle tone and enhance cognition.
Narcolepsy can be a serious and debilitating neurological condition that causes dysregulation of the sleep-wake cycle and is characterized clinically by excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, sleep paralysis, and disrupted nocturnal sleep. It is estimated that 185,000 individuals in the U.S. are affected with Narcolepsy. Cataplexy is seen in an estimated 70% of narcolepsy patients and is a sudden reduction or loss of muscle tone while a patient is awake, typically triggered by strong emotions such as laughter, fear, anger, stress, or excitement.
US Food and Drug Administration (FDA) grants Breakthrough Therapy Designation for AXS-12 for the treatment of cataplexy in patients with narcolepsy.